Use of the haematopoietic progenitor cell parameter in optimizing timing of peripheral blood stem cell harvest

Vox Sang. 2009 Aug;97(2):153-9. doi: 10.1111/j.1423-0410.2009.01183.x. Epub 2009 Apr 9.

Abstract

Background and objectives: Timing of peripheral blood stem cell (PBSC) harvest is typically based on quantification of peripheral blood (PB) CD34+ cells. CD34 enumeration is expensive, requires expertise and takes a minimum of 1-2 h to perform. The Sysmex XE2100 is an automated haematology analyser that can rapidly and inexpensively identify haematopoietic progenitor cell (HPC) populations in PB. The aim of this study was to examine if HPC can be used to optimize timing of PBSC harvest.

Materials and methods: White blood cell (WBC), HPC and CD34 counts were determined in a total of 60 mobilized donors. Data were analysed to examine the utility of WBC and HPC counts in predicting preharvest CD34+ counts.

Results: In adults presenting for autologous collection, a PB HPC threshold of > 30/microl predicts a preharvest CD34+ count of > 20/microl with sensitivity of 86% and positive predictive value (PPV) of 100%. Among paediatric patients with a diagnosis of neuroblastoma, an HPC threshold of > 16/microl yielded sensitivity and PPV of 100%, while in children with other diagnoses, an HPC cut-off of > 44/microl yielded sensitivity and PPV of 67% and 100%, respectively. Eighty per cent of adequately mobilized allogeneic donors were identified using an HPC threshold > 15/microl, with a PPV of 100%. PB WBC can also aid in predicting CD34 counts in most patient groups, albeit with lower sensitivity than HPC.

Conclusion: By virtue of being a sensitive and accurate predictor of preharvest CD34+ counts, our data support the use of the HPC parameter in optimizing the timing of PBSC harvest.

Publication types

  • Evaluation Study

MeSH terms

  • Adult
  • Antigens, CD34
  • Child
  • Hematopoietic Stem Cell Mobilization / instrumentation
  • Hematopoietic Stem Cell Mobilization / methods*
  • Hematopoietic Stem Cells / cytology*
  • Humans
  • Leukocyte Count
  • Neuroblastoma / therapy
  • Peripheral Blood Stem Cell Transplantation / methods
  • Time Factors
  • Transplantation, Autologous

Substances

  • Antigens, CD34